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Abstract
Tumor vasculature expresses a distinct set of molecule signatures on the endothelial cell surface different from the
resting blood vessels of other organs and tissues in the body. This makes them an attractive target for cancer
therapy and molecular imaging. The current technology using the in vivo phage display biopanning allows us to
quickly isolate and identify peptides potentially homing to various tumor blood vessels. Tumor-homing peptides in
conjugation with chemotherapeutic drugs or imaging contrast have been extensively tested in various preclinical
and clinical studies. These tumor-homing peptides have valuable potential as targeting probes for tumor molecular
imaging and drug delivery. In this review, we summarize the recent advances about the applications of tumor-
homing peptides selected by in vivo phage display library screening against tumor vasculature. We also introduce
the characteristics of the latest discovered tumor-penetrating peptides in their potential clinical applications.
Background
Up to now, cancer remains one of the leading causes of
patients’ deaths worldwide. Successful prevention and
treatment of cancer depends on the precise detection at
the early stage. Conventional anatomic imaging techniques
such as computed tomography (CT) and magnetic reso-
nance imaging (MRI) typically detect tumours when their
sizes are bigger than a centimetre in diameter [1,2]. It is
evident that more sensitive imaging technologies are
needed to be developed to provide early and accurate diag-
nosis for cancers. Molecular imaging technologies are con-
sidered promising methods because they obtain the
information through monitoring the key molecular beha-
viours and host responses related to early events in disease
development and progress at the cellular and molecular
levels [1,3]. Compared with traditional imaging techniques
which are mainly based on anatomical structures of
organs, molecular imaging usually utilizes specific molecu-
lar probes targeting unique receptors (molecules) of tumor
tissues or other diseased tissues to form the localized pic-
tures of image contrast[4]. Thus, it becomes the key point
to identify and generate the tumor-specific molecular
ligands with high binding affinity.
Likewise, as far as cancer treatment is concerned, tar-
geted drug delivery is attracting intensive attention
because it can not only enhance the local drug concentra-
tion but also reduce the systemic side effect due to non-
specific exposure of anti-cancer drugs to normal tissues.
The targeted drug delivery is usually defined as an anti-
cancer drug attached by an appropriate tumor-targeting
ligand which creates so-called “magic bullet or smart bul-
let” to produce explosive effects only at the tumor site[5].
Taken together, both of the molecular imaging and tar-
geted drug delivery need tumor-specific ligands to bridge
the gap between anti-cancer drug/imaging contrast and
tumor tissues. To this end, specific ligands should have
the ability to discriminate tumor tissues from normal
organs.
Traditionally, antibodies or their fragments are the
most common molecular targeting agents for the speci-
fic delivery of imaging contrast and anti-cancer drugs to
tumor sites. Several monoclonal antibodies have been
used in clinics for cancer therapy in the non-conjugated
or conjugated manner, such as Trastuzumab (for breast
cancer), Bevacizumab (for colorectal cancer), Cetuximab
(for colorectal cancer/head and neck cancer) and
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Ibritumomab tiuxetan (for Non-Hodgkin lymphoma)
[5-10]. However, there are two main disadvantages
which greatly limit the antibody application, namely the
low tumor tissue penetrating ability due to the large size
of molecules and nonspecific uptake by the mononuc-
lear phagocyte system (MPS) [6,11]. The advent of pep-
tide library has extended the range of target agents to a
great extent and exhibit many unique characteristics
when compared with antibody. For instance, peptides
display good tissue penetrating ability due to small
molecular weight (averagely less than 50 amino acids),
low immunogenicity, high affinity to targets, acceptable
stability and integrity in vivo and easy to manipulate for
synthesis and conjugation with other agents [6,11,12].
Phage-displayed peptide library provides us with a possi-
bility to identify and achieve peptide ligands binding to
target protein through biopanning the library containing
more than billions of peptides. In the past two decades,
the phage display technology has undergone a series of
important changes and breakthrough developments.
Originally, phage peptide library selection was carried
out against soluble protein coated in the solid phase. By
now, whole cells, tissue samples and live animals have
been extensively used as baits to capture feasible binding
peptides from a variety of phage libraries [13-15]. These
new panning methods are more likely to keep native
structure and functional conformation of target proteins
than purified protein. Furthermore, they require no pre-
vious knowledge of the molecular composition at the
site of interest. The peptides so obtained by these meth-
ods would possess high affinity and specificity on target
sites.
For tumor targeting, ample evidence has indicated that
cancer cells and tumor endothelial cells express a dis-
tinct set of molecules on their surface that are different
from normal cells and blood vessels respectively. This
makes cancer cells and tumor vasculature become
potential targets for ligand-mediated diagnosis and drug
delivery [16,17]. However, what is the better bait for
phage peptide screening to identify tumor targeting
probes remained to be studied.
Tumor cells vs tumor vasculature as targets
Cancer cells express a large number of receptors on their
surface. Some receptors are overexpressed and mediate
important biological functions in tumor growth, migration,
invasion and metastasis. Theoretically cancer cell is an
excellent target for therapy and imaging. Conventional
chemotherapy drugs are mainly designed to target cancer
cells. However, it is difficult for these drugs to be absorbed
by cancer cells because they can seldom accumulate into
tumor mass due to poor blood perfusion, high interstitial
pressure and abnormal vasculature inside the tumor mass
[18,19]. In fact cancer cells are genetically unstable and
often produce multidrug resistance to multiple che-
motherapeutic drugs which is also considered as one of
major reasons for the failure of cancer therapy [20-22].
Cultured cells which are usually utilized as target for pep-
tide screening might lost tissue-specific characteristics or
abnormally express some molecules that do not actually
exist in the corresponding cells in vivo[23,24]. In contrast
with tumor cells, endothelial cells of tumor display several
advantages which promote tumor vasculature an attractive
target for peptide discovery [5,18,25,26]. Tumor endothe-
lial cells have the good genetic stability so that they rarely
produce drug resistance. Tumor blood vessels are also
highly accessible to any intravenously administered agents.
A great quantity of data based on genomics and proteo-
mics approaches have implicated that endothelial cells
(from tumor mass or other organs) express distinct pat-
terns of molecules regulated by their original organ tissues
and microenvironment, which are the most important fac-
tors for selectivity and a prerequisite for phage peptide
selection [27-29]. The unique zip codes of vasculature in
different tissues exert vital roles in organ-specific physiolo-
gical function or disease/tumor development[16].
In vivo phage display
Peptides recognizing specifically the tumor vasculature
are promising agents to efficiently deliver drugs and ima-
ging contrast to tumor sites. Tumor angiogenesis, the
sprouting and growth of new blood vessels, is indispensi-
ble for tumor growth, development and progression
[30,31]. Neovascularization of tumors not only provides
nutrients and oxygen necessary to tumor growth through
blood supply, but also carry cancer cells to adjacent/dis-
tant organs to induce metastasis [30,32]. It is likely that
destruction of tumor vasculature will halt the tumor
blood supply and further restrict tumor progression. In
vivo phage peptide selection pioneered by Ruoshlahti’s
laboratory since 1996[13] has been extensively exploiting
the discovery of peptides targeting the vasculature in nor-
mal organs or angiogenesis-related diseased tissues. In
brief, the procedure of in vivo phage library selection is
closely similar to the classical in vitro screening based on
the “binding-washing-eluting-amplifying” process against
purified proteins. Only the target is now changed into
live animal model. The phage peptide library is intrave-
nously injected into animals and allowed to circulate for
5-15 minutes. It is understood that phage cannot leave
the circulation in such a short period of time and the
homing peptides displayed on the phage coat protein are
able to bind to the target molecules expressed on the
endothelial cells in the blood vessels. The subsequent
phage enriching screening would allow the target phage
to selectively bind to tumor blood vessels [11,27,33].
Using this method numerous peptides targeting the
tumor vasculature have been identified. Some of the
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peptides are also found to recognize cancer cells besides
tumor blood vessels owing to the fact that they may
share the similar and related receptors in endothelial and
cancer cells. Therefore these peptides may serve addi-
tional advantages as excellent candidates for drug deliv-
ery and cancer treatment [18,34-36].
Peptides targeting tumor vasculature
It has been shown that peptides obtained from the in
vivo phage library selection against various tumor vascu-
latures are capable to efficiently deliver drug/imaging
contrast to tumor sites. To this end some peptide conju-
gates are being tested in clinical studies and achieved
promising results. Table 1 gave a summary of tumor
vasculature-homing peptides discovered in recent years
through in vivo phage library screening.
Directed drug delivery by targeting-vasculature peptides
Arginine-glycine-aspartic acid (RGD) and asparagine-gly-
cine-arginine (NGR) peptides are the two most famous
peptides targeting tumor vasculature discovered earlier
by phage display. RGD peptide can home to tumor vas-
culature selectively expressing avb3 and avb5 integrins,
and NGR peptide (CNGRC) binds to CD13 specifically
expressed in tumor vasculature [37]. Although intergrins
are also expressed in normal tissue cells and blood ves-
sels, endothelial cells in angiogenic vessels express a
distinct set of integrins from its repertoire in quiescent
endothelial cells [38]. avb3 and avb5 integrins are specifi-
cally upregulated in tumor endothelial cells undergoing
angiogenesis [38,39]. The RGD peptide with two internal
disulfide bonds recognizes selectively to avb3 and avb5
integrins, which promote RGD peptide or its conjuga-
tions to accumulate in tumor vasculature [40]. Similarly,
CD13 is not exclusively expressed in tumor neovascula-
ture. But NGR peptide specifically targets CD13 molecule
expressed in tumor blood vessels rather than other
CD13-rich tissues [36,41]. The exact mechanism so far
remains unknown, but it is speculated that a unrevealed
CD13 isoform is expressed in tumor blood vessels which
might be involved in different glycosylation modification
or conformational changes[36,42].
The two peptides have become a classic tool to be used
to deliver various anti-cancer drugs including but not lim-
ited to chemotherapeutic drugs, cytokines, toxins, nucleic
acids, radioactive isotopes and nanoparticles [37,43-46].
RGD and NGR peptides coupled with doxorubicin can
specifically induce destruction of tumor vasculature in the
breast cancer xenograft model in nude mice and further
inhibit tumor growth but have no obvious cytotoxic effect
on the vasculature of control organs. When conjugated
with a pro-apoptotic peptide D(KLAKLAK)2 which by
itself has no activity outside the cells, RGD/NGR peptides
could deliver this pro-apoptotic peptide into the tumor
Table 1 Peptides targeting tumor blood vessels
Sequence (no. of amino acids, name) Tumor types tested Receptors Applications References
CDCRGDCFC(9, RGD) Various tumor types avb3 and avb5
integrins





Various tumor types CD13 TD and TT [36,37]
CTPSPFSHC(9, TCP-1) Orthotopic colorectal cancer and
gastric cancer












HL-60 human leukemia tumor
MDA-MB-435 tumors
Nucleolin ND [35,65]
CSRPRRSEC(9) HPV16-induced dysplastic skin
CGKRK(5) and CDTRL(5) HPV16-induced skin carcinoma
Breast carcinomas
ND ND [58]




CRGDK/RGPD/EC (9, iRGD) Various tumor types av integrins and
neuropilin-1
TD and TT [63,64]
CPRECESIC(9) EF43-fgf4-derived breast tumor
MDA-MB-435-derived breast tumor
Aminopeptidase A TT [96]
CGNSNPKSC(9, GX1) Gastric cancer ND TD and TT [97]
SVSVGMKPSPRP (12, SP5-52) Several cancers ND TT [56]
*Not determined
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vasculature through respective receptors. As a result, the
conjugate selectively induced apoptosis of tumor endothe-
lial cells and reduced the tumor growth as well as pro-
longed survival rate in animals [44]. NGR peptide
(CNGRC) was also fused with human tumor necrosis
factor alpha (TNF alpha) protein to constitute a new
recombinant protein which could greatly enhance the
activity of TNF alpha at very lower dose (0.3 μg) in tumor-
bearing mice [47]. Further investigation disclosed that
subnanogram (0.1 ng) of NGR-TNF alpha could synergis-
tically enhance the tumor toxicity of doxorubicin and
melphalan, cisplatin, paclitaxel, and gemcitabine in mouse
tumor models, but did not increase the side effects [46].
Phase 1b study of NGR-TNF alpha was tested at low dose
in combination with doxorubicin to patients with
advanced solid tumors. Results showed that NGR-TNF
alpha seldom induced a dose-limited systemic toxicity
which previously limited TNF alpha usage for systemic
treatment. Patients could well tolerate the side effects
when TNF alpha and NGR combined [48]. Phase 1 clinical
trial also showed similar conclusions [49]. Similarly, RGD
peptide was also proven to be able to significantly enhance
anti-tumor activity of TNF alpha at subnanogram level
when combined with melphalan in tumor-bearing mice
[50]. In addition to TNF alpha, other important cytokines
such as truncated tissue factor (tTF), interferon gamma
(IFN gamma) and interleukin-12(IL-12) which have great
potential as anti-cancer agents, have been fused with
NGR/RGD peptides or other peptides targeting tumor
blood vessels to enhance their anti-cancer activity [51-55].
In recent years, other novel peptides exhibiting the hom-
ing ability to tumor blood vessels were also reported from
different laboratories worldwide and tested in various
systems [56-60]. Recently, we identified a vasculature-
targeting peptide TCP-1 (CTPSPFSHC) using the in vivo
phage library selection against an orthotopic colorectal
cancer model. TCP-1 peptide can specifically recognize
the blood vessels of orthotopic colorectal cancer in normal
BABL/c mice induced by syngeneic colon cancer cells
(colon 26) [19] and also orthotopic gastric cancer in nude
mice induced by human gastric cancer cells (unpublished
data). We also illustrated that TCP-1 peptide could effi-
ciently deliver the fluorescein and the apoptosis-inducing
peptide D(KLAKLAK)2 to the tumor site for imaging and
targeted therapy. TCP-1 peptide appears to be a promising
agent in molecular imaging and drug delivery for human
gastrointestinal cancers since preliminary data shows that
it could also recognize the blood vessels in colorectal
cancer samples in humans.
It is envisaged that peptides simultaneously recognizing
the tumor vasculature and cancer cells are more effective
for cancer therapy than those only targeting tumor blood
vessels or cancer cells. Such peptides like NGR and GRD
display a dual targeting ability. TCP-1 peptide was also
found to be able to bind to some colorectal cancer cells
(unpublished data). This kind of peptide conjugate there-
fore not only can exert targeted anti-cancer function but
also provide selective anti-angiogenesis therapy. However,
in order to achieve both actions the dose of the new con-
jugate should be large so as to be able to fully infiltrate
into the tumor mass which has a high interstitial pressure
and abnormal vasculature structure. The conjugate may
only penetrate three to five cell diameters close to blood
vessels [18,61]. Recently, the discovery of tumor-penetrat-
ing peptides might hold good promise for increasing over-
all tumor accumulation and penetration abilities of drugs
to a great extent. The peptides containing the consensus
motif R/KXXR/K (R: arginine, K: lysine, X: any amino
acids) [24] can bind to neourophilin-1 (NRP-1) protein
expressed on the cell surface. The arginine or lysine in the
C-terminal is indispensible for the binding activity. The
peptide internally containing the motif can be cleaved by
protease to expose the C-terminal so that the binding
activity to NRP-1 is switched on (termed C-end rule,
CendR). NRP-1 is a cell-surface receptor expressed in var-
ious cells and is also found to be overexpressed in tumor
tissues [62]. Normally NRP-1 is involved in angiogenesis,
regulation of vascular permeability, and development of
the nervous system. It is suggested that CendR peptide
can increase the vascular permeability, penetrate tissues in
vivo through binding to NRP-1 of endothelial cells after
intravenous injection [24]. The peptide CRGDKGPDC
(termed iRGD) obtained through the in vivo phage library
screening against experimental metastasis mouse model of
human prostate cancer contains both RGD and CendR
(RGDK) motifs [63]. Further studies showed that i.v.
injected iRGD was first recruited to tumor endothelial
cells through RGD motif interacting with integrins, and
subsequently the CendR motif exposed by the proteolytic
cleavage finished the interaction with NRP-1 which drove
the peptide to cross the vascular wall and penetrate into
the tumor parenchyma. iRGD peptide chemically conju-
gated with abraxane (a 130 nm albumin-based nanoparti-
cle embedded paclitaxel) could increase more than 4-fold
drug accumulation in tumor tissues when compared to
conventional RGD conjugates [63]. Moreover, co-adminis-
tration of the iRGD peptide with various anti-cancer drugs
but not chemical conjugation also highly enhanced
the drug penetration and accumulation and improved
their therapeutic index [64]. Actually, several early-discov-
ered peptides may have the tumor-penetrating activity
similar to iRGD because they contain a potential CendR
motif, such as F3 (a 31 amino acid peptide homing to
cancer cells and tumor endothelial cells) [65], LyP-1
(CGNKRTRGC), homing to cancer cells, tumor macro-
phages and lymphatic vessels [66], CREKA and
CSRPRRSEC (two peptides homing to tumor blood
vessels) [58,67].
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Directed molecular imaging by targeting-vasculature
peptides
The tumor-homing peptides have been investigated in var-
ious imaging detection system for tumor diagnosis includ-
ing MRI, positron emission tomography (PET), single
photon emission computed tomography (SPECT) and
fluorescence confocal microendoscope when they are
coupled with different dyes or imaging agents [68]. RGD
and NGR are extensively used to deliver different imaging
agents for molecular imaging studies in various tumor
types or other angiogenesis diseases. [18F]-labelling RGD
conjugate has been developed for PET diagnosis and
administered to patients with squamous cell carcinoma of
the head and neck (SCCHN) [69]. Results showed that
[18F]-labelling RGD can successfully produce specific ima-
ging in avb3-expression SCCHN patients and the conju-
gate may be useful to assess angiogenesis and response of
avb3-targeted therapies for patients with SCCHN [69].
Other phase I trial of PET based on 18F-AH111585/RGD
conjugate has been performed in breast cancer patients
[70]. The conjugate is retained in the tumor tissues and
can detect the breast cancer by PET. Many other agents
have also been coupled with RGD peptide for imaging
detection such as (64)Cu, (68)Ga [71], near infrared fluor-
escent [72] and 99mTc [73]. Recently, RGD or NGR pep-
tide coupled with nanoparticles (quantum dots) was tested
in mice tumor model for molecular imaging [74-76]. Intra-
venous injection of NGR peptide-labelled paramagnetic
quantum dots (NGR-pQDs) into tumor-bearing mice was
used to evaluate the angiogenesis activity of tumors by the
MRI system [76]. NGR-pQDs were found to be capable of
specifically detecting the tumor region with the highest
angiogenic activity [76].
TCP-1 peptide identified by our laboratory was labelled
by FITC and administered to mice bearing orthotopic
colorectal tumor for ex vivo detection under the blue
light. The simple conjugate was found to accumulate
within the tumor mass with a high specificity, and even it
could produce obvious signal in tumor mass as small as
2 millimetres in the ex vivo level. If this situation can be
reproduced in clinical setting, TCP-1 peptide conjugate
combined with PET, MRI or endoscope may improve the
diagnosis of patients with colorectal cancer[19].
For the newly discovered peptide iRGD, the iRGD
peptide-linked superparamagnetic iron oxide nano-
worms can produce hypo-intense vascular signals and
low intensity regions in the tumor mass detected by
MRI after intravenous injection into tumor-bearing mice
[63]. Its effect is obviously better than the conventional
RGD peptide for tumor visualization. Histological stain-
ing confirms that iRGD nanoworms have the ability to
more deeply penetrate into the tumor tissues than the
RGD conjugate, suggesting the great potential of iRGD
as a diagnostic agent in clinical practice[63].
Several points worthy of being considered on tumor
vasculature-targeting peptides
To date, the mouse tumor model of subcutaneous inocu-
lation is the most frequently applied in cancer-related
studies. For the discovery of tumor-homing peptides, a
series of peptides have been successfully identified
through selecting the phage library in vivo against subcu-
taneous xenograft model in immunodeficient mice
[56,77,78]. However, subcutaneous cancer xenograft
model cannot actually mimic the complex microenviron-
ment of organs from which cancer cells originate. Thus,
the interpretation of experimental results conducted
under these conditions sometimes suffers from signifi-
cant limitations, especially for the identification of vascu-
lature-targeting peptides. It is because microenvironment
is actually a vital element which regulates the balance of
pro- angiogenic and anti-angiogenic cytokines and deter-
mines the angiogenic heterogeneity in tumor mass
[79-81]. A growing number of literatures have indicated
that various cancer cells interplay with their surrounding
microenvironments to influence angiogenesis, cancer cell
proliferation, apoptosis, invasion and metastasis [82-85].
A typical example is that human renal cell carcinoma
inoculated orthotopically in the kidney of nude mice can
produce 10-20 fold higher level of bFGF mRNA than
those subcutaneous tumors induced by the same cell
line, and orthotopic tumor is highly metastatic and vas-
cularized [86]. Therefore, in our opinion, the orthotopic
tumor model is more suitable to select the vasculature-
homing peptides to a greater extent. Chances are that
more compatible peptides to species from mice to
humans can be discovered by this condition. In fact the
TCP-1 peptide isolated by our laboratory was found not
to target the colorectal tumor induced subcutaneously by
the same cell line or other colorectal cancer cells except
to recognize the vasculature of orthotopic colorectal can-
cer (induced by mouse cancer cell in normal BALB/C
mice) [19]. Similar findings have also been reported in
two other studies by Ruoslahti’s lab [58,59]. They isolated
three vasculature-homing peptides against a mouse
model of HPV16-induced epidermal carcinogenesis that
could distinguish the progressive vascular changes based
on this model. But none of them could home to the vas-
culature of angiogenic dysplasia or tumor in the RIP-Tag
transgenic mouse model of pancreatic islet carcinoma
whose tumors were located at different site with tumor
model used in the course of selection. On the other
hand, they variably targeted the vasculature of other
tumor types growing in or under the skin [58]. Similarly,
other study also found that five peptides homing to neo-
plastic lesion in the pancreas could not target the subcu-
taneous islet cell tumor induced by a human cancer cell
line or other tumors developed subcutaneously [59]. All
these data imply that the microenvironment plays a
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crucial role in the development and expression of pheno-
types in the tumor vasculature.
Tumor microenvironment is often infiltrated by various
inflammatory cells such as lymphocytes, mast cells, neu-
trophils and macrophages which can secrete a variety of
cytokines, growth factors and chemokines [82]. These
inflammatory mediators are involved in the tumor angio-
genesis to a great extent. It is noted that chronic inflam-
mation often accompanies with tissue regeneration and
angiogenesis, and even increases the risk of certain
cancers. There is no surprise that some tumor vascula-
ture-homing peptides also bind to blood vessels of some
inflammatory diseases because of the sharing distribution
of certain biomarkers between tumors and inflammatory
tissues. For instance, RGD and NGR peptides can also
home to blood vessels of collagen-induced arthritis [87],
hypoxia-induced retinopathy [88] and ischemic heart
[89], all of which are associated with inflammation and
angiogenesis. Undoubtedly these findings extend further
the scope of application for these peptides. However,
under certain circumstances, tumor might coexist with
diseases associated with inflammation and angiogenesis
such as cerebral ischemia, myocardial infarction and
arthritis. Tumor-targeted therapy to destruct the blood
vessels might be not suitable in this situation. Therefore,
tumor type-specific homing peptides would be more
likely to solve the problem. In our study, we found that
TCP-1 peptide could not recognize the neovasculature of
acute and chronic colitis in mice induced by dextran sul-
fate sodium (DSS) though chronic inflammatory bowel
diseases are directly related to colorectal cancers (unpub-
lished data), suggesting the binding site of TCP-1 peptide
in the blood vessels is a marker for tumors but not for
inflammatory tissues in the same organ.
The binding sites or receptors of tumor-homing pep-
tides are another important and interesting issue to be stu-
died because the receptor identification would likely
produce new biomarkers for tumor diagnosis and therapy.
This could lead to a new mechanism for tumor angiogen-
esis and development. To this end new ligands can be gen-
erated to target at this mechanism. However, in contrast
with quick discovery of many tumor-homing peptides,
identification of receptors is slower and relatively difficult.
Only a small number of homing peptides are found
together with their receptors through protein pull-down
assay or affinity chromatography combined with protein
mass spectrometry [24,90-92]. Intrinsic characteristics of
membrane protein might be responsible for the low suc-
cess rate for receptor identification. It is likely that there
may be difficult to prepare these binding sites. The low
solubility and the destruction of structural conformation
of these binding sites may lead to a decrease of ligand affi-
nity during tissue preparation. The other possibility that
cannot be excluded is that the receptors might not be
proteins, but the motifs of lipids or carbohydrates located
on the cell surface.
Finally, nanoparticles applied in cancer diagnosis and
therapy may have resulted in the advent of a novel
field ‘nanomedicine’. Nanoparticles as drug delivery
vectors or imaging probes have been developed and
exhibit many superior properties such as better tumor
penetrating ability, high capability to carry payloads of
therapeutic agents, high quality of imaging information
and limited toxicity [93,94]. Nanoparticles combined
with tumor-homing peptides can further enhance the
targeting ability of nanoparticles and produce more
efficient anti-cancer effect and more specific imaging
information, which might represent a promising and
attractive direction for tumor-targeted diagnosis and
therapy.
Conclusions
To sum up, in vivo phage peptide selection provides us
with great opportunities to isolate peptides homing to
blood vessels of diseased tissues. Since its inception in
1996 creatively developed by Erkki Ruoshlahti [13],
numerous vasculature-homing peptides have been identi-
fied and tested widely in different models with various
interests. On the other hand, these peptide discoveries also
prove the concept of vascular zip codes that the endothe-
lial cells in each organ express a distinct set of cell surface
molecules. Tumor-homing peptide studies greatly extend
the scope of tumor-targeted diagnosis and therapy and
produce novel tools as target probes to efficiently and spe-
cifically deliver drugs and imaging agents to tumor sites.
Identification of tumor-penetrating property of these pep-
tides further extends their potential for tumor-targeted
diagnosis and therapy.
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